Cancer Epidemiology
Volume 36, Issue 2 , Pages 153-160, April 2012

Estimation of disease prevalence, true positive rate, and false positive rate of two screening tests when disease verification is applied on only screen-positives: A hierarchical model using multi-center data

  • Eileen M. Stock

      Affiliations

    • Department of Statistical Science, P.O. Box 97140, Baylor University, Waco, TX 76798-7140, USA
    • Department of Statistical Science, Baylor University, Waco, TX 76798, USA
    • Center for Applied Health Research, Scott & White Healthcare System, Temple, TX 76502, USA
    • Corresponding Author InformationCorresponding author at: Department of Statistical Science, P.O. Box 97140, Baylor University, Waco, TX 76798-7140, USA. Tel.: +1 254 710 1699; fax: +1 254 710 4477.
  • ,
  • James D. Stamey

      Affiliations

    • Department of Statistical Science, Baylor University, Waco, TX 76798, USA
  • ,
  • Rengaswamy Sankaranarayanan

      Affiliations

    • Screening Group, International Agency for Research on Cancer, Lyon, France
  • ,
  • Dean M. Young

      Affiliations

    • Department of Statistical Science, Baylor University, Waco, TX 76798, USA
  • ,
  • Richard Muwonge

      Affiliations

    • Screening Group, International Agency for Research on Cancer, Lyon, France
  • ,
  • Marc Arbyn

      Affiliations

    • Unit of Cancer Epidemiology, Scientific Institute of Public Health, Brussels, Belgium

Received 30 April 2011; received in revised form 24 June 2011; accepted 6 July 2011. published online 25 July 2011.

Abstract 

Objectives: A model is proposed to estimate and compare cervical cancer screening test properties for third world populations when only subjects with a positive screen receive the gold standard test. Two fallible screening tests are compared, VIA and VILI. Methods: We extend the model of Berry et al. [1] to the multi-site case in order to pool information across sites and form better estimates for prevalences of cervical cancer, the true positive rates (TPRs), and false positive rates (FPRs). For 10 centers in five African countries and India involving more than 52,000 women, Bayesian methods were applied when gold standard results for subjects who screened negative on both tests were treated as missing. The Bayesian methods employed suitably correct for the missing screen negative subjects. The study included gold standard verification for all cases, making it possible to validate model-based estimation of accuracy using only outcomes of women with positive VIA or VILI result (ignoring verification of double negative screening test results) with the observed full data outcomes. Results: Across the sites, estimates for the sensitivity of VIA ranged from 0.792 to 0.917 while for VILI sensitivities ranged from 0.929 to 0.977. False positive estimates ranged from 0.056 to 0.256 for VIA and 0.085 to 0.269 for VILI. The pooled estimates for the TPR of VIA and VILI are 0.871 and 0.968, respectively, compared to the full data values of 0.816 and 0.918. Similarly, the pooled estimates for the FPR of VIA and VILI are 0.134 and 0.146, respectively, compared to the full data values of 0.144 and 0.146. Globally, we found VILI had a statistically significant higher sensitivity but no statistical difference for the false positive rates could be determined. Conclusion: Hierarchical Bayesian methods provide a straight forward approach to estimate screening test properties, prevalences, and to perform comparisons for screening studies where screen negative subjects do not receive the gold standard test. The hierarchical model with random effects used to analyze the sites simultaneously resulted in improved estimates compared to the single-site analyses with improved TPR estimates and nearly identical FPR estimates to the full data outcomes. Furthermore, higher TPRs but similar FPRs were observed for VILI compared to VIA.

Keywords: Sensitivity and specificity, Hierarchical Bayesian model, Mixed logit model, Diagnostic or screening

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S1877-7821(11)00107-X

doi:10.1016/j.canep.2011.07.001

Cancer Epidemiology
Volume 36, Issue 2 , Pages 153-160, April 2012